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Not only is there a limited supply of organs for liver transplantation, but the quality of the available organs is not uniform.
Risk factors such as donor age and cause of death are known to predict graft failure, but their impact on the recipient’s
quality of life (QOL) has not been reported. We sent a QOL survey to 299 adults at our institution who had received a liver
transplant 1 to 7 years before the study. For the 171 patients (57%) who completed the Medical Outcomes Study Short
Form 36 (SF-36), the mean Physical Composite Score (PCS) and the mean Mental Composite Score (MCS) were 61 and
66, respectively; the highest scores were for the Social Functioning subscale, and the lowest scores were for the Role
Functioning/Physical and Energy/Fatigue subscales. The mean donor risk index (DRI) of the organs that the subjects
received was 1.4 (range ¼ 0.8-2.4). There was no correlation between the SF-36 scores and the DRI [there were changes
of 4.8 and 2.8 in the PCS and MCS per unit increase in the DRI (P ¼ 0.4 and 0.6, respectively)], even though we con-
trolled for potential confounders such as age, sex, hospitalization before transplantation, the Model for End-Stage Liver Dis-
ease score at transplantation, years since transplantation, previous transplantation, and the Charlson comorbidity index. In
conclusion, we found no association between organ quality and QOL after liver transplantation. If this ﬁnding is conﬁrmed in
prospective, multicenter studies, it will be useful in counseling patients about the decision to accept or not accept high-risk
organ offers. Liver Transpl 17:1443-1447, 2011. VC 2011 AASLD.
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Although liver disease ranks 12th overall among
causes of death in the United States, the true impact
on society is likely much larger because people are
affected in the prime of their lives. In fact, liver dis-
ease ranks fourth overall among causes of death for
people 45 to 54 years old.1 Furthermore, end-stage
liver disease leads to dysfunction in virtually every
organ system, and this results in a very poor quality
of life (QOL) for those affected.2 Liver transplantation
has become the best treatment for most patients with
end-stage liver disease; it prolongs survival3 and
improves QOL.2 One of its main limitations continues
to be the limited supply of organs.
The organ supply is not ﬁxed but rather depends on
multiple factors, including the quality of the organs
that are accepted for use. Various donor factors are
known to be associated with the risk of graft failure
after transplantation; these include the donor’s age,
the anticipated ischemia time, and donation after car-
diac death.4 Whenever an organ offer is made, the
physician and the patient must make the difﬁcult de-
cision to accept the organ being offered or to wait and
hope that a better organ will be offered.
One limitation to a physician’s ability to counsel a
patient about this decision is the lack of information
on the ways in which donor characteristics affect a
recipient’s QOL, which is deﬁned by the World Health
Organization as ‘‘individuals’ perceptions of their posi-
tion in life in the context of the culture and value sys-
tems in which they live and in relation to their goals,
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expectations, standards, and concerns.’’5 In other
words, if a patient accepts a higher risk organ and sur-
vives, will he or she experience the same QOL as a re-
cipient of an average quality liver? The answer to this
question is particularly important because most high-
risk organs are transplanted into patients with low
Model for End-Stage Liver Disease (MELD) scores6;
these patients are predicted to derive little survival
beneﬁt from transplantation7 and thus may be under-
going transplantation predominantly to improve their
QOL. Therefore, the aim of this study was to determine
whether organ quality is associated with posttrans-
plant QOL in liver transplant recipients.
PATIENTS AND METHODS
Subject Population
A QOL survey was mailed to adults who underwent
deceased donor liver transplantation 1 to 7 years
before the study. This time period was chosen
because previous studies have shown that QOL after
liver transplantation continues to rise until approxi-
mately 1 year after transplantation, at which time it
plateaus.2 Recipients of combined transplants were
excluded. Clinical and demographic characteristics
were obtained from medical charts, and the Deyo
adaptation of the Charlson comorbidity index was
obtained from billing data.8 Posttransplant variables
were obtained through the review of individual charts,
and they included the hospital length of stay, renal
failure requiring dialysis after the transplant hospital-
ization, biliary complications requiring a percutane-
ous transhepatic cholangiogram tube, and biopsy-
proven rejection. Informed consent was obtained for
participation, and this study was approved by our
institutional review board.
QOL Measurements
We used the Medical Outcomes Study Short Form 36
(SF-36) instrument because it had been previously used
in liver transplant recipients and is more sensitive than
other instruments to small changes.9 The 36 items com-
bine to form the Physical Composite Score (PCS) and
the Mental Composite Score (MCS), which range from
0 to 100, as well as 8 subscales: Physical Functioning,
Role Functioning/Physical, Role Functioning/Emo-
tional, Energy/Fatigue, Emotional Well-Being, Social
Functioning, Pain, and General Health.10 Scores are
reported in raw scale units unless otherwise noted.
Organ Quality
The organ quality was measured with the donor risk
index (DRI),4 a continuous measure in which each
unit increase over 1 denotes an incremental risk of
graft failure with respect to the best quality organs.
The individual components of the DRI include the fol-
lowing: the donor’s age, race, height, and cause of
death; the donation after cardiac death status; the
organ type (split versus whole); the share type (re-
gional or national); and the cold ischemia time.
Except for the cold ischemia time (which was obtained
from our hospital’s transplant database), these data
were obtained directly from our organ procurement
organization. Imputation was performed for 12 of the
171 subjects (7%) with missing cold ischemia times,
and an imputation ﬂag was created to ensure that no
bias was introduced by this method.11 When subjects
had received multiple liver transplants, the data from
the most recent transplant was used.
Statistical Analysis
Bivariate comparisons were performed with the t test
and Pearson’s chi-square statistic for continuous and
categorical data, respectively. Multivariate linear
regression was used to determine variables independ-
ently associated with the raw scores of the SF-36 PCS
and MCS as well as the 8 subscales. Although the
SF-36 scores were not normally distributed, residual-
versus-ﬁtted plots demonstrated no evidence of heter-
oskedasticity and thus supported the use of paramet-
ric methods. Power calculations showed that a sample
size of 139 would be sufﬁcient to detect a 10-unit
decrease in the SF-36 score caused by the DRI (10%
of the overall SF-36 range) if b ¼ 0.8 and a ¼
0.05 were assumed. Calculations were performed with
Stata 11.0 (StataCorp, College Station, TX).
RESULTS
The QOL survey was sent to 299 transplant recipi-
ents, and it was completed by 171 (57%). The
respondents were less likely to be Hispanic than the
nonrespondents (2% versus 11%, P ¼ 0.03) but other-
wise did not differ from the nonrespondents with
respect to age, sex, race/ethnicity, primary diagnosis,
or years since transplantation. The demographic
characteristics of the survey respondents and the
entire population of adult liver transplant recipients
at our center during the study period are listed in
Table 1.
The mean SF-36 PCS and MCS values for the 171
respondents were 61 and 66, respectively, and they
were consistent with the ﬁndings of other studies of
liver transplant recipients.12 As shown in Table 2, in
comparison with the US population, the transplant
recipients appeared to have lower PCS values but sim-
ilar MCS values.13 Nineteen percent indicated that
their QOL had not improved since transplantation or
had gotten worse.
The mean DRI of the organs received by the study
subjects was 1.4 6 0.4, which was consistent with
the organ quality in our transplant region.11 In com-
parison, the mean DRI for the entire population of
adult liver transplant recipients at our center during
the study period was also 1.4. The rates of death and
graft failure in the entire transplant population during
the study period were 27% and 31% for recipients of
organs with a DRI  1.6 (n ¼ 310) and 36% and 38%
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for recipients of organs with a DRI > 1.6 (n ¼ 154;
P ¼ 0.04 and P ¼ 0.1, respectively).
The DRI distribution for the survey respondents is
shown in Fig. 1. Subjects who received a transplant in
more recent years tended to have higher DRI organs,
and so did those with lower laboratory MELD scores
at transplantation (P < 0.05 for both comparisons).
However, there was no association between the DRI
and posttransplant QOL by the PCS, the MCS, or any
individual subscale. When the organs were catego-
rized into high-risk organs (DRI > 1.6) and standard-
risk organs, the PCS and MCS were 61 and 66,
respectively, in the standard risk group and 60 and
66, respectively, in the high-risk group (P ¼ not signif-
icant). As shown in Table 3, this lack of an associa-
tion persisted even after we controlled for multiple
potential confounders, including the recipient’s age
and sex, the years since transplantation, the MELD
score at transplantation, the history of previous trans-
plantation, the comorbidity index, and the hospitali-
zation status immediately before transplantation.
Subjects who reported that their QOL had not
improved with transplantation were distributed
equally according to the quality of the organs that
they had received: 18% in the standard-risk group
and 24% in the high-risk (DRI > 1.6) group (P ¼ 0.4).
Posttransplant complications are shown in Table 4
for subjects who received standard-risk organs and
subjects who received high-risk organs. In this popu-
lation of study patients who survived for at least 1
year after transplantation, the recipients of high-risk
organs had similar lengths of stay in comparison with
the recipients of standard-risk organs, and they were
TABLE 1. Demographics of the Survey Respondents and All Adult Deceased Donor Liver Transplant Recipients at the
Center During the Study Period
Survey Respondents
(n ¼ 171)
All Adult Liver Transplant
Recipients (n ¼ 464)
Age at transplantation (years) 53 (18-70) 53 (18-71)
Male sex [n (%)] 105 (61) 280 (60)
Race/ethnicity [n (%)]
White 144 (84) 376 (81)
Black 13 (8) 41 (9)
Hispanic 3 (2) 18 (4)
Other 11 (6) 29 (6)
Primary diagnosis [n (%)]
Viral 38 (22) 115 (25)
Alcohol 20 (12) 59 (13)
Cryptogenic/fatty liver 21 (12) 56 (12)
Hepatocellular carcinoma 34 (20) 101 (22)
Cholestatic 28 (16) 64 (14)
Other 30 (18) 69 (15)
Laboratory MELD score at
transplantation [median (range)]
19 (6-40) 18 (6-40)
Previous liver transplantation [n (%)] 13 (8) 39 (8)
TABLE 2. SF-36 Scores of the Survey






PCS 61 6 25 43
MCS 66 6 22 49
Physical Functioning 67 6 26 43
Role Functioning/Physical 51 6 44 42
Role Functioning/Emotional 68 6 41 45
Energy/Fatigue 51 6 24 47
Emotional Well-Being 73 6 18 49
Social Functioning 75 6 26 46
Pain 62 6 30 47
General Health 56 6 24 43
NOTE: Raw scores are expressed as means and standard
deviations on a 0 to 100 scale, whereas norm-based
scores are compared to 1998 US population data with a
mean of 50 and a standard deviation of 10.
Figure 1. DRI distribution for the organs received by the study
subjects.
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no more likely to require dialysis or a percutaneous
transhepatic cholangiogram tube. The recipients of
high-risk organs had lower rates of biopsy-proven rejec-
tion than recipients of standard-risk organs (P ¼ 0.01).
DISCUSSION
This study has found that organ quality, as measured
by the DRI, does not appear to affect posttransplant
QOL. The SF-36 PCS and MCS values were virtually
identical for subjects who received standard-risk organs
and subjects who received high-risk organs (DRI > 1.6).
This lack of a clinically or statistically signiﬁcant associ-
ation persisted despite adjustments for multiple poten-
tial confounders, such as age, medical comorbidities,
and the pretransplant severity of liver disease.
It is important to reiterate that subjects in this
study had to survive for at least 1 year after trans-
plantation to be included, and the time since trans-
plantation was 4 years on average. Because the DRI is
known to be a strong predictor of graft failure within
the ﬁrst 1 to 3 years, the QOL implications of these
ﬁndings are contingent upon the survival of patients
for these ﬁrst years. This survival bias likely explains
the lack of an association between organ quality and
posttransplant complications. Additionally, not all
patients experienced improvements in QOL: 19% felt
that they were no better or were even worse since
transplantation. Therefore, patients can be counseled
as follows: if they accept a high-risk organ and do not
die from graft failure, their QOL may be no worse than
it would have been if they had received a standard-risk
organ. Indeed, their QOL would be much better than it
would have been if they had died on the waiting list,
and this could be the outcome for patients with high
MELD scores who decline a high-risk organ.
The ﬁrst limitation of this study is the relatively
small proportion of very high-risk organs (DRI > 2).
Further studies are needed to determine whether
such organs, which are less than 10% of liver trans-
plants nationwide,11 are associated with worse QOL
after transplantation. Second, the sample size was
powered to detect a 10-unit change in the SF-36 score.
A less than 10-unit impact of organ quality on QOL
could be clinically signiﬁcant and could have been
missed. Third, this was a single-center study. Varia-
tions in surgical techniques at different centers could
theoretically interact with organ quality and thus inﬂu-
ence posttransplant QOL via biliary complications or
other complications. Furthermore, variations between
centers in organ utilization and recipient/graft match-
ing might limit the generalizability of these ﬁndings. A
ﬁnal limitation of this study is its cross-sectional
design, which may be less sensitive than a longitudinal
design for the detection of minor changes in QOL and
also fails to account for pretransplant QOL. It is possi-
ble that patients with worse pretransplant QOL tended
to receive better quality organs, even after we con-
trolled for variables such as the MELD score.
In summary, organ quality does not appear to affect
QOL after liver transplantation, at least among recipi-
ents of low- to moderate-risk organs and among
patients who survive at least 1 year after transplanta-
tion. If these ﬁndings are conﬁrmed in multicenter,
TABLE 3. Multivariate Analysis of Pretransplant Factors Associated With the SF-36 PCS and MCS
Factor
PCS MCS
Coefﬁcient P Value Coefﬁcient P Value
DRI 4.8 0.4 2.8 0.6
Sex 0.8 0.8 4.7 0.2
Current age (years) 0.3 0.3 0.2 0.3
MELD score at transplantation 0.2 0.5 .06 0.8
Years since transplantation 0.3 0.8 0.6 0.5
Previous transplantation 11.5 0.2 10.9 0.1
Charlson comorbidity index 0.1 0.9 0.5 0.4
Hospitalized at transplantation 2.7 0.7 4.7 0.4
NOTE: Coefﬁcients should be interpreted as changes in the SF-36 score per unit increase in the DRI.
TABLE 4. Posttransplant Complications According to the Quality of the Organ
Complication
High-Risk Organ (DRI > 1.6)
Recipients (n ¼ 52)
Standard-Risk Organ
Recipients (n ¼ 119) P Value
Length of stay [days; median (range)] 10 (5-69) 10 (4-101) 0.2
Dialysis beyond transplant hospitalization [n (%)] 2 (4) 14 (12) 0.1
Biliary complications requiring percutaneous
transhepatic cholangiography [n (%)]
7 (13) 14 (12) 0.8
Biopsy-proven rejection [n (%)] 3 (6) 26 (22) 0.01
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prospective studies, they can be used to counsel
patients when they are making difﬁcult decisions
about organ acceptance.
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